BIOSTAR PHARM-B (02563) announced that the latest clinical research data from four studies on its core products, UTD1 injection and UTD2 capsules, have been selected for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The four selected studies focus on: a Phase I/II clinical trial of UTD2 for advanced breast cancer; a Phase II clinical trial of UTD2 for platinum-resistant ovarian cancer; a Phase II clinical trial of UTD1 for HER2-positive advanced breast cancer; and a Phase II clinical trial of UTD1 for castration-resistant prostate cancer. Leveraging the broad anti-cancer spectrum and high oral bioavailability of utidelone, BIOSTAR PHARM-B continues to advance its strategic development in new indication expansion and clinical development of oral formulations. The 2026 ASCO Annual Meeting is scheduled to take place from May 29 to June 2, 2026, at the McCormick Place Convention Center in Chicago, USA. The annual ASCO meeting brings together leading global clinical oncology experts to showcase the latest international advancements in clinical oncology research and cancer treatment technologies.